Bisphosphonates for malignancy-related bone disease: current status, future developments.

Bisphosphonates for malignancy-related bone disease: current status, future developments.

Item
http://www.wikidata.org/entity/Q36383420
Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent mannerγδ T cells in cancer immunotherapyTargeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancerA promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice.Multiple myeloma/hypercalcemia.A primer of bone metastases management in breast cancer patients.Skeletal bone diseases impact the periodontium: a review of bisphosphonate therapy.The use of bisphosphonates in cancer patients.Significance and impact of bisphosphonate-induced acute phase responses.Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer.Treatment options for breast cancer and bone metastases.Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.Geranylgeranyl diphosphate synthase inhibition induces apoptosis that is dependent upon GGPP depletion, ERK phosphorylation and caspase activation.The correlation between lateral bowing angle of the femur and the location of atypical femur fractures.Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol.
P2860

Bisphosphonates for malignancy-related bone disease: current status, future developments.

Item
http://www.wikidata.org/entity/Q36383420
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Bisphosphonates for malignancy-related bone disease: current status, future developments.
@ast
Bisphosphonates for malignancy-related bone disease: current status, future developments.
@en
type
label
Bisphosphonates for malignancy-related bone disease: current status, future developments.
@ast
Bisphosphonates for malignancy-related bone disease: current status, future developments.
@en
prefLabel
Bisphosphonates for malignancy-related bone disease: current status, future developments.
@ast
Bisphosphonates for malignancy-related bone disease: current status, future developments.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Bisphosphonates for malignancy-related bone disease: current status, future developments.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P698